Investor · 1 deal
Every published round Ally Bridge Group took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| AdvanCell | Series D+ | 15 Jul 2026 | $450m | Lead | Forbes Australia (3 Sep 2026), Forbes Australia (16 Jul 2026), Brandon Capital, advancell.com.au, Brandon Capital portfolio, Brandon Capital portfolio, Tenmile portfolio |
Companies Ally Bridge Group has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AdvanCell | Produces radiopharmaceuticals that target cancer cells without the typical collateral dam… | 15 Jul 2026, Series D+ | 1 | 1 |
Fund closes reported for Ally Bridge Group, as distinct from the investments it has made.
Companies Ally Bridge Group has backed that another company then bought. An exit for the holding, not a deal Ally Bridge Group did.
| Name | Role | Sources |
|---|---|---|
| Andrew Lam | Managing Director and Head of Biotech Private Equity | Brandon Capital, advancell.com.au |
Stories naming Ally Bridge Group. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brisbane radiopharmaceutical developer AdvanCell has closed an oversubscribed Series D round, led by Ally Bridge Group and Alpha Wave with several institutional investors returning, to fund late-stage prostate cancer trials and US manufacturing.